ClinicalTrials.gg
RecruitingNCT06767631Updated Apr 29, 2026

Pilot Study on Muscle, Tendon, and Neural Changes Post-Botulinum Toxin Injections in Post-stroke Spastic Equinovarus

An interventional study of threedimensional freehand ultrasound and instrumented spasticity assessment in Stroke, Spasticity and Equinovarus Foot, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
40 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Stroke by Universitaire Ziekenhuizen KU Leuven — 4 open to participants now, 4 under way, none of them phase 3. Stroke · Universitaire Ziekenhuizen KU Leuven.

Started
2025
with 1 other
No phase
6 of 11
3 open now
Registered
10th of 11
by date

Among the 11 studies in Stroke by Universitaire Ziekenhuizen KU Leuven, this one is one of 2 that started in 2025, is one of 6 with no phase, and was the 10th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

4 of the 11 studies in Stroke by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 40 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Stroke by Universitaire Ziekenhuizen KU Leuven, or all of them as a file.
02

Study summary

Poststroke spasticity significantly impairs function, particularly through the development of pes equinovarus. Botulinum toxin A (BoNT) injections into the medial gastrocnemius (MG) are a first-line treatment. Treatment outcomes and long-term responses to interventions can vary significantly between individual patients. Additionally, there is increasing concern about potential adverse effects on muscle morphology. Further research is essential to optimize treatment strategies and improve long-term outcomes in this population. Three-dimensional freehand ultrasound (3DfUS) and instrumented spasticity assessment (ISA) are two recently developed techniques that enable the evaluation of changes in muscle, tendon, and neural properties following BoNT injections for post-stroke spastic equinovarus. These methods hold promise for providing new insights into treatment effects. Before implementing these techniques in large-scale studies, a pilot study is required for accurate sample size calculations for a prospective observational study. This study includes a protocol for a non-blinded, non-randomized open-label longitudinal pilot study. The study was approved by the European Medicines Agency ( EU CT Number 2024-513158-32) by the University Hospitals Leuven ethical committee (ID S68672). Standard deviations and effect sizes of outcome measures obtained longitudinally with 3DfUS and ISA before and after BoNT injection into MG will inform sample size calculations for future research.

Read the detailed description

TRIAL RATIONALE:

To conduct a pilot study as guidance for a future observational study to evaluate changes in muscle, tendon and neural properties after botulinum neurotoxin-A (BoNT) treatment of spastic equinovarus in first-ever stroke patients by using Three Dimensional freehand Ultrasound (3DfUS) and Instrumented Spasticity Assessment (ISA) with the aim of optimizing treatment algorithms and long-term response in this population.

TRIAL DESIGN:

Non-blinded, non-randomized open label, longitudinal pilot interventional clinical trial.

In total, 4 visits will be organised:

  1. V1: Baseline visit, week 0
  2. V2: Injection visit, week 5-7
  3. V3: Follow-up visit, week 10-12:
  4. V4: End of study visit , week 18-30

4 visits are organized according to the biological functioning of BoNT. These 4 visits also correspond to the standard clinical visits as they currently proceed when a patient is treated with BoNT. At baseline visit (week 0) and injection visit (week 6) we do not expect any changes in outcome parameters since no BoNT has been injected yet. The effect of BoNT has peak effects after 4-6 weeks and a duration of action between 2 and 6 months. At follow-up visit (week 10-12) and end-of-study visit (when BoNT is clinically elaborated, week 18-30) we expect corresponding changes in outcome parameters, respectively.

At each visit, 3DfUS measurements and ISA measurements will be performed on two muscles of both legs: 1) medial gastrocnemius muscle and 2) tibialis anterior muscle. The majority of US literature in the lower limb has focused on medial gastrocnemius. Additionally, these muscles are obvious candidates because of their functional importance in locomotion. Moreover, the medial gastrocnemius is a frequently injected muscle with BoNT, whereas tibialis anterior muscle is not. From a methodological perspective, both medial gastrocnemius and tibialis anterior are superficial and can be easily tracked by means of conventional US probes and EMG electrodes.

During visit 2, a pregnancy test will be conducted prior to the injection of Botulinum toxin. If the test is positive, the study will be discontinued, and the patient will not be treated with Botulinum toxin A.

Total duration of one visit will be 1.5 to 2 hours. All measurements of one visit take place on the same day. Measurements will be performed at the University Hospital Leuven.

For this study, stroke patients treated with BoNT for spastic equinovarus will be included. In particular stroke patients are patients that are being treated at the University Hospital, Leuven. The annual number of stroke patients seen in UZ Leuven is approximately 600 per year.

03

Conditions studied

  • Stroke
  • Spasticity
  • Equinovarus Foot

Keywords

  • Botulinum Toxins
  • stroke
  • Medial Gastrocnemius Muscle
  • Skeletal muscle morphology
  • muscle composition
04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary written of the participant or their legally authorized representative has been obtained prior to any screening procedures
  • 2. At least 18 years of age at the time of signing the Informed Consent Form (ICF)
  • 3. Use of highly effective methods of ; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.
  • 4. Pes equinovarus due to spasticity
  • 5. Clinical need for BoNT injection at the lower leg
  • 6. Any previous injection of BoNT into the muscles to be investigated was at least 3 months ago
  • 7. First-ever, unilateral stroke

Exclusion criteria

Exclusion Criteria:

  • Musculoskeletal or other neurological problems affecting the lower limb
  • Presence of spinal cord pathology that could lead to spasticity, ataxia, dystonia
  • Cognitive problems that impede measurements
  • Severe co-morbidities
  • Irritated skin or open wounds where ultrasound will be placed
  • Pregnancy
  • Profound atrophy of the muscles in the target area(s) of injection
  • Participation in an interventional Trial with an medicinal product (IMP) or device
  • The effect of botulinum toxin A can theoretically be potentiated by agents affecting neuromuscular transmission, such as aminoglycoside antibiotics (e.g., gentamicin, tobramycin), lithium salts, cholinesterase inhibitors and tubocurarine-like muscle relaxants ((cis)atracurium, rocuronium, suxamethonium, vecuronium). Therefore, patients on whom these medications are started during the course of the trail will be excluded.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Other
    stroke patients treated with Botulinum toxine injections for spastic equinovarus

    This study involves a single-arm, exploratory, longitudinal design focusing on first-time stroke patients with spastic equinovarus deformity. Participants will receive Botulinum Neurotoxin Type A (BoNT-A) injections targeting medial and lateral gastrocnemius muscle as well ass soleus muscle. The intervention aims to assess changes in muscle, tendon, and neural properties before and after treatment by using instrumented spasticity assessment and threedimensional freehand ultrasound

    Diagnostic Test: threedimensional freehand ultrasound and instrumented spasticity assessment

Interventions

  • Diagnostic testthreedimensional freehand ultrasound and instrumented spasticity assessment

    To conduct a pilot study as guidance for a future observational study to evaluate changes in muscle, tendon and neural properties after botulinum neurotoxin-A (BoNT) treatment of spastic equinovarus in first-ever stroke patients by using Three Dimensional freehand Ultrasound (3DfUS) and Instrumented Spasticity Assessment (ISA) with the aim of optimizing treatment algorithms and long-term response in this population.

06

What researchers measure

Primary outcomes

  1. sample size calculation

    To estimate the number of subjects to calculate an appropriate sample size for assessing changes in muscle, tendon and neural properties after BoNT treatment of spastic equinovarus in first-ever stroke patients by using 3DfUS and ISA in a future observational study. To calculate standard deviation and effect sizes of outcome measures obtained with 3DfUS and ISA in these patients.

    Time frame: 2 years

Secondary outcomes

  1. muscle changes

    Secondary outcome parameters measured by 3DfUS include muscle belly length for medial gastrocnemius muscle

    Time frame: 2 years

  2. neural changes

    Secondary outcome parameters measured by ISA for slow stretch measured by ISA : maximal velocity of performance (Vmax \[deg/s\])

    Time frame: 2 years

  3. functional changes

    Medical baseline data including age, gender, body mass index, time since stroke, stroke etiology, National Institute Health Stroke Scale \[15\], affected side, oral medication and adverse events will be collected at each visit from the patients medical file as they are part of standard of care:

    Time frame: 2 years

  4. muscle changes

    Secondary outcome parameters measured by 3DfUS include tendon length for medial gastrocnemius muscle

    Time frame: 2 years

  5. muscle changes

    Secondary outcome parameters measured by 3DfUS include mid-belly cross-sectional area for medial gastrocnemius muscle

    Time frame: 2 years

  6. muscle changes

    Secondary outcome parameters measured by 3DfUS include muscle belly length for tibial anterior muscle

    Time frame: 2 years

  7. muscle changes

    Secondary outcome parameters measured by 3DfUS mid-belly cross-sectional area for tibial anterior muscle

    Time frame: 2 years

  8. muscle changes

    Secondary outcome parameters measured by 3DfUS include mean Echo Intensity for tibial anterior muscle

    Time frame: 2 years

  9. muscle changes

    Secondary outcome parameters measured by 3DfUS include mean Echo Intensity for medial gastrocnemius muscle

    Time frame: 2 years

  10. neural changes

    Secondary outcome parameters measured by ISA for slow stretch measured by ISA : range of motion \[deg\]

    Time frame: 2 years

  11. neural changes

    Secondary outcome parameters measured by ISA for slow stretch measured by ISA: stiffness \[Nm/deg\]

    Time frame: 2 years

  12. neural changes

    Secondary outcome parameters measured by ISA for slow stretch measured by ISA work \[J\] (area under the power-time curve).

    Time frame: 2 years

  13. neural changes

    Secondary outcome parameters measured by ISA from the fast stretch: maximal velocity of performance (Vmax \[deg/s\])

    Time frame: 2 years

  14. neural changes

    Secondary outcome parameters measured by ISA from the fast stretch: joint angle of catch \[deg\]

    Time frame: 2 years

  15. neural changes

    Secondary outcome parameters measured by ISA from the fast stretch: angle of EMG threshold \[deg\]

    Time frame: 2 years

  16. neural changes

    Secondary outcome parameters measured by ISA from the fast stretch: intensity of catch (power \[W\]; torque times angular velocity).

    Time frame: 2 years

  17. functional changes

    Modified Asworth Scale

    Time frame: 2 years

  18. functional changes

    Tardieu scale

    Time frame: 2 years

  19. functional changes

    Barthel Index

    Time frame: 2 years

  20. functional changes

    Functional Ambulation Categories

    Time frame: 2 years

  21. functional changes

    the Rivermead Mobility Index

    Time frame: 2 years

  22. functional changes

    Functional Independence Measure

    Time frame: 2 years

  23. functional changes

    Fugl-Meyer scale

    Time frame: 2 years

  24. functional changes

    Modified Rankin Scale

    Time frame: 2 years

  25. functional changes

    5 Meter Timed Walking Test

    Time frame: 2 years

  26. functional changes

    Motricity Index

    Time frame: 2 years

  27. functional changes

    Five-Times Sit-to-Stand Test

    Time frame: 2 years

  28. functional changes

    Gait analyses

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hanssen B, De Beukelaer N, Schless SH, Cenni F, Bar-On L, Peeters N, Molenaers G, Van Campenhout A, Van den Broeck C, Desloovere K. Reliability of Processing 3-D Freehand Ultrasound Data to Define Muscle Volume and Echo-intensity in Pediatric Lower Limb Muscles with Typical Development or with Spasticity. Ultrasound Med Biol. 2021 Sep;47(9):2702-2712. doi: 10.1016/j.ultrasmedbio.2021.04.028. Epub 2021 Jun 8. PubMed 34112554 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 24 months is close to that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2024
First posted
Jan 10, 2025
StartActual
May 2, 2025
Primary completionEst.
May 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06767631
Responsible party
Sponsor
First posted
Jan 10, 2025
Start date
May 2, 2025
Primary completion
May 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 29, 2026

Study contacts

Fabienne Schillebeeckx, MD, PI
Contact
fabienne.schillebeeckx@uzleuven.be
0032 - 16338714
Fabienne Schillebeeckx, MD,PI
Contact
fabienne.schillebeeckx@uzleuven.be
0495100300
Fabienne Schillebeeckx, MD
principal investigator · UZ Leuven campus Pellenberg, secretariaat fysische geneeskunde en revalidatie blok 5

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion